Research & Education

NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials Lung-MAP and ALCHEMIST, the first “Master Protocol” trials

DENVER – The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute (NCI) sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration (FDA), academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

Less costly to screen for and treat early-stage lung than to treat late-stage lung cancer.

DENVER – The average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography (LDCT) plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

Modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy.

DENVER – There were only modest acute changes in cardiac biomarkers and electrocardiograms and there were no clinically significant cardiac events in patients with high-dose radiation exposure to the heart following thoracic radiation therapy (RT) and short-term follow-up.

Abstracts for LALCA 2014 now published in the JTO.

DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to announce that scientific abstracts for the 6th Latin American Conference on Lung Cancer (LALCA) are now available online through the Journal of Thoracic Oncology.

BIM deletion predicts survival in advanced non-small cell lung cancer.

DENVER – Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. Also, BIM deletion independently predicts overall survival (OS) of advanced NSCLC patients.

High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer.

DENVER – Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA.

Pages